Battles for Origin Energy, OZ Minerals and Pendal-Perpetual have had the spotlight on public company M&A, but tonight we’re back hunting in the world of private equity.
TPG Capital is readying a big bolt-on acquisition for its clinical testing tearaway, Novotech.
The deal, should it be signed, would make Novotech a truly global CRO. It’s expected to add about 15 per cent to the company’s top line, but the more significant thing is the extension of its footprint.
The acquisition would come only six months after Novotech bolted on a US business, to go with its powerful network in Asia.
Australian born-and-bred clinical research organisation Novotech is preparing to make a big splash in Europe with the acquisition of Poland-based EastHORN Clinical Services.